The DEFB104A antibody targets the human β-defensin 104A (DEFB104A), a member of the β-defensin family involved in innate immunity. β-defensins are small, cationic antimicrobial peptides encoded by the DEFB gene cluster, playing critical roles in microbial defense, wound healing, and immune modulation. DEFB104A, also known as defensin beta 104. is expressed primarily in epithelial tissues, including the skin, respiratory tract, and reproductive organs, where it contributes to barrier function by disrupting microbial membranes and recruiting immune cells via chemotactic signaling. Its expression can be upregulated in response to pathogens or inflammatory stimuli.
Antibodies against DEFB104A are valuable tools for studying its localization, expression patterns, and functional interactions in both healthy and diseased states. They enable researchers to investigate its role in infections, chronic inflammation, and cancers, where defensin dysregulation is often observed. For example, DEFB104A antibodies are used in techniques like Western blotting, immunohistochemistry, or flow cytometry to quantify protein levels or visualize tissue distribution. Additionally, these antibodies aid in exploring DEFB104A’s potential as a biomarker or therapeutic target, particularly in conditions like psoriasis, atopic dermatitis, or certain carcinomas. Commercial DEFB104A antibodies are typically validated for specificity, often through knockout controls or peptide blocking assays, ensuring reliability in experimental settings. Ongoing research continues to unravel its broader immunomodulatory functions, including interactions with receptors like CCR6 and involvement in signaling pathways linked to inflammation.